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spheroids: a tool for modulating chemosensitivity traits†
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Peter Lampen,a Joachim Franzke,a Jan G. Hengstler,b Cristina Cadenas,a Leoni A. Kunz-Schughartc
and Jonathan West*a
Received 10th June 2010, Accepted 12th October 2010
DOI: 10.1039/c0lc00089bWe report the use of thin film poly(dimethylsiloxane) (PDMS) prints for the arrayed mass production
of highly uniform 3-D human HT29 colon carcinoma spheroids. The spheroids have an organotypic
density and, as determined by 3-axis imaging, were genuinely spherical. Critically, the array density
impacts growth kinetics and can be tuned to produce spheroids ranging in diameter from 200 to
550 mm. The diffusive limit of competition for media occurred with a pitch of $1250 mm and was used
for the optimal array-based culture of large, viable spheroids. During sustained culture mass transfer
gradients surrounding and within the spheroids are established, and lead to growth cessation, altered
expression patterns and the formation of a central secondary necrosis. These features reflect the
microenvironment of avascularised tumours, making the array format well suited for the production of
model tumours with defined sizes and thus defined spatio-temporal pathophysiological gradients.
Experimental windows, before and after the onset of hypoxia, were identified and used with an enzyme
activity-based viability assay to measure the chemosensitivity towards irinotecan. Compared to
monolayer cultures, a marked reduction in the drug efficacy towards the different spheroid culture
states was observed and attributed to cell cycle arrest, the 3-D character, scale and/or hypoxia factors.
In summary, spheroid culture using the array format has great potential to support drug discovery and
development, as well as tumour biology research.Introduction
Monolayer cell cultures are traditionally used as in vitro models to
investigate the cancer process and identify effective anti-tumour
therapies. These planar models do not recapitulate the tissue
architecture, cell–cell and cell–matrix interactions, and mass
transfer barriers and associated metabolic gradients of avascular
tumour nodules, micrometastases or intervascular tumour
regions. This limits their predictive value, leading to the potential
failure of therapies during in vivo trials, or the failure of potentially
effective therapies to progress to further testing phases. As an
alternative, the multicellular tumor spheroid model has emerged
as a powerful spherical tissue model with authentic cell–cell
interactions and complete radial symmetry for the establishment
of uniform mass transfer gradients typical of the tumour niche.1,2aLeibniz—Institut f€ur Analytische Wissenschaften—ISAS—e.V.,
Otto-Hahn-Str. 6b, 44227 Dortmund, Germany. E-mail: west@isas.de
bLeibniz Research Centre for Working Environment and Human Factors at
the University of Dortmund (IfADo), Ardeystr. 67, 44139 Dortmund,
Germany
cOncoRay—Center for Radiation Research in Oncology, Tumor
Pathophysiology, TU Dresden, Fetscherstraße 74, 01307 Dresden,
Germany
† Electronic supplementary information (ESI) available: Thin film
PDMS printing (Fig. S1), assembly and growth video, integrin and
E-cadherin gene expression (Fig. S2), BT474 and NCI-H1792 spheroid
arrays (Fig. S3), volumetric growth (Fig. S4), necrosis onset (Fig. S5)
and details of the chemosensitivity experiment (Table S1). See DOI:
10.1039/c0lc00089b
‡ nee Menne.
This journal is ª The Royal Society of Chemistry 2011Multicellular tumour spheroids are traditionally produced by
a variety of methods which share the common feature of resisting
cell–surface interactions to promote cell–cell coupling and the
aggregation of dense cellular assemblies. One strategy involves
the continuous agitation of the cell suspension within spinner
flasks, roller tubes, gyratory shakers or rotating wall vessels.1,3
These methods are suitable for large scale production, but are
lengthy and produce heterogeneously sized spheroids. Alterna-
tively, for smaller scale operations, the aggregation process can
be achieved by sedimentation onto concave and cell adhesion
resistant surfaces, such as microtitre plate wells coated with
agarose,4 poly-hydroxyethyl methacrylate (poly-HEMA),5 or
a droplet’s air–liquid interface.6–8 These methods compartmen-
talize the aggregation of individual spheroids and result in the
formation of homogeneously sized spheroids. However, these
methods suffer the drawbacks of being tedious, manually
intensive and with a limited scope for mass production. To drive
the widespread implementation of the spheroid model in routine
anti-cancer therapy testing programs new automated methods
for the scalable production of tumour spheroids with uniform
characteristics are required.2
Tissue engineering approaches have been used to tackle the
problem by encapsulating the aggregation process within scaf-
fold pockets formed by templating monodisperse microparti-
cles9,10 or droplets prepared within a two-phase microfluidic
reactor.11 Microfluidics has also received great interest as
a means to provide continuous perfusion during compartmen-
talized spheroid assembly. Devices are fabricated from poly-
(dimethylsiloxane) (PDMS) for ease of replication and its cellLab Chip, 2011, 11, 419–428 | 419
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View Article Onlineadhesion resistance properties.12,13 To avoid disrupting aggre-
gation a bilayer system incorporating a semi-porous membrane
can be used to vertically interface the culture chamber with
a perfusion channel,14–18 or rows of micropillars can be used to
interface a central culture chamber with neighbouring perfusion
channels.19,20 To similar effect, hydrodynamic traps can also be
used to shelter cellular aggregates during continuous perfusion.21
Microwell arrays can also be used to cage the assembly process
during stationary culture. Here, the cells settle from suspension
into discrete populations of equivalent number for the auto-
mated culture of uniformly sized spheroids. The microwell
format can be highly parallelized for the high density culture of
spheroids numbering in their thousands. Microwell arrays have
been fabricated in poly(methyl methacrylate) (PMMA) by UV-
LIGA,22 or in PDMS using anisotropically etched silicon23 or
microstructured SU-8 moulds.24–26 Poly(ethylene glycol) (PEG) is
another preferred material which enables spheroid formation by
resisting cell adhesion, with microwell arrays either made by
embossing a PEG material layer27 or by the self-assembly of
thiolated PEG molecules onto platinum-coated PMMA micro-
wells.28 Collagen29,30 or Arg-Gly-Asp peptide31 adhesion islands
have also been microcontact printed (mCP) onto the base of the
microwells to centre spheroid growth. Importantly, adhesion
patterns alone can be used to direct the centre of cell assembly
and partition growth for the parallel culture of spheroids. Here,
the physical walls of microfluidic and microwell systems are
replaced with a biologically inert background such as PEG
brushes or hydrogels.32–36 This planar compartmentalization
strategy enables unconstrained growth with improved mass
transfer for nutrient supply and waste removal.
The vast majority of microtechnology-based spheroid
production methods have focused on the development of 3-D
liver tissue models for the maintenance of hepatocyte-specific
biochemical and metabolic functions or for the controlled and
synchronized differentiation of stem cells into embryoid bodies.
In this paper we instead report the use of thin film PDMS
micropatterning for the controlled culture of uniform and
metabolically relevant tumour spheroids and demonstrate the
value of this approach for cancer research and drug discovery
applications.Materials and methods
Microarray-based spheroid culture
Throughout this study hexagonally arrayed cell adhesion islands
with a diameter of 150 mm were patterned on glass substrates
across an area of 20  20 mm. Arrays with different adhesion
island pitches and different numbers of adhesion islands were used
in this study: 400 mm (2411), 450 mm (25 sub-arrays totalling
1675), 700 mm (739), 1000 mm (409), 1250 mm (263), 1500 mm
(149) and 2000 mm (104). As illustrated in ESI Fig. S1†, cell
patterning was achieved by thin film PDMS microcontact printing
as described previously by Frimat and co-workers.13 Briefly, SU-8
moulds were prepared by standard photolithographic methods
and used to cast PDMS (Sylgard 184, Dow Corning) stamps at
70 C for 20 minutes. The SU-8 mould incorporates protruding
circular structures for the fabrication of PDMS stamps with
recessed features. The stamps were inked by contact transfer420 | Lab Chip, 2011, 11, 419–428for 10 s with a liquid PDMS deposit prepared by spin coating
a 500 mL volume of PDMS prepolymer and curing agent dissolved
in chloroform (1 : 10, w/w) for 30 s at 6000 rpm. Printing was also
achieved by contact transfer for10 s. A sacrificial print was used
to remove excess liquid PDMS for subsequent precision printing
on glass substrates. Thermal curing at 70 C for 10 minutes was
used to produce a stable thin film PDMS perforation pattern
exposing areas of the underlying substrate. The glass surface
bordering the pattern was also passivated with PDMS to restrict
cells to the adhesion islands alone.
Human colon carcinoma cells (HT29), BT474 breast carcinoma
and NCI-H1792 lung carcinoma cell lines were purchased from
DSMZ (Germany) and ATCC (USA). Cells were cultured in
Dulbecco’s modified Eagle media (DMEM) supplemented with
10% (v/v) foetal bovine serum (or 10% (v/v) foetal bovine serum
gold (PAA, Germany) for the HT29 cell line), 1% (v/v) Glutamax,
and 1% (v/v) penicillin and streptomycin (Sarstedt AG & Co.,
Germany). Cells were cultured at 37 C in a humidified atmo-
sphere with 6% CO2, and harvested using trypsin/EDTA once 80–
90% confluency was attained. The arrays were placed within
hydrophobic, bacteriological grade Petri dishes (Ø¼ 55 mm) and
seeded with a 1 mL media suspension containing 2 105 cells and
incubated for 3 days prior to gentle washing and media exchange
to remove non-adherent cells. Following cell patterning a 6 mL
media volume was periodically exchanged every 2–3 days. For off-
chip analysis spheroids were harvested by pipetting.Physical characterisation
The spheroids were documented using an inverted microscope
(IX71, Olympus). High resolution spheroid array images were
obtained using an environmental SEM (Quantam200F, FEI)
operating at 90 Pa. SEM imaging required fixation. The arrays
were incubated twice in 1 PBS for 5 minutes and then fixed for
24 hours in SAV neutral buffered 4% formaldehyde (Liquid
Production, Germany), followed by a final 1 PBS wash for
5 minutes and air drying for a further 24 hours. The spheroid
arrays were coated with gold for electron imaging. Spheroid
morphology was determined by 3-axis imaging, with circularity
measurements using ImageJ (NIH). Spheroids were first
embedded in a hydrated agarose environment by insertion into
molten 2% (w/v) agarose, followed by cooling for gelation. A
razor blade was used to cut agarose cubes for straightforward 3-
axis positioning. The spherical nature of the spheroids enables
the tissue density to be estimated from the sedimentation velocity
(assuming steady-state motion). Spheroid sedimentation veloci-
ties within a 1 PBS column were recorded and a derivation of
the Stoke’s equation was used to calculate the density:
rs ¼ rf þ

9hvs
2rs2g

where rs is the spheroid density, rf the fluid density, h the fluid
viscosity (1.002  103 kg m1 s1), vs the sedimentation velocity,
rs the spheroid radius and g gravity (9.8 m s
2). For each growth
condition, five 3-axis measurements were taken. The number of
cells per spheroid involved pooling 30 spheroids in triplicate. The
supernatant was removed and the spheroids were treated with
trypsin for 30 minutes at 37 C with vortexing every 5 minutes. A
100 mL volume of this single cell suspension was diluted in 10 mLThis journal is ª The Royal Society of Chemistry 2011
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View Article OnlineCasyton for cell counting with a Casy instrument (Innovatis
AG, Germany).
The Gompertz equation can be used to accurately model the
volumetric growth of avascularised spherical tissues.37–39 The
spheroid volume at a given time, V(t), is given by:
VðtÞ ¼ Vð0Þ  expa=bð1exp
bt Þ
where V(0) is the initial spheroid volume, a is the growth
regression rate and b is a growth retardation constant. The
Gompertz equation was used to evaluate the growth behaviour
of spheroids on microarrays with pitches ranging from 400 to
2000 mm. The spheroid volume, Vs, was calculated from the
diameter using a capped spherical model:
Vs ¼ (4/3pr3)  (ph(3a2  h2)/6)
where r is the radius of a sphere (spheroid), a the radius of the cap
(adhesion island) and h the height of the cap.Biological characterisation
Gene expression analysis. For reverse transcription quantita-
tive polymerase chain reaction (RT-qPCR) analysis, RNA was
isolated from spheroid and monolayer cultures using QIAzol
Lysis Reagent (Qiagen) following the manufacturer’s protocol.
Two micrograms of total RNA were reverse-transcribed using
random primers and the High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems). RT-qPCR was undertaken
with an ABI Prism 7700 (Applied Biosystems) and the Quanti-
Tect SYBR Green PCR Kit (Qiagen). QuantiTect primer assays
(Qiagen) were used for the amplification of all gene expression
targets: actin (QT01680476); a5b1-integrin (QT00068124);
E-cadherin (QT00080143); PCNA (QT00024633); cyclin D
(QT004925285); p21 (QT00062090); and VEGF-A
(QT01682072). Amplification involved a 15 minute hot start at
95 C, followed by 40 cycles of denaturation at 94 C for 15 s,
annealing at 60 C for 30 s, extension at 72 C for 35 s, and
finishing with ramping from 55 C to 95 C to generate melting
curves. Data were analysed using the 2DDCt method40 with actin
used as the housekeeping gene and the untreated monolayer
cultures used as the calibrator. Each condition was undertaken in
triplicate, with each sample measured in triplicate.
Section staining. For imaging tissue sections, spheroids were
embedded in 1% agarose, fixed in 4% buffered formaldehyde
overnight at 4 C, and subsequently embedded in paraffin for
cutting into 4 mm thick sections using a microtome (Microm
HM450). Immediately prior to staining, the paraffin was
removed by rinsing in Rotihistol (4  5 minutes), followed by
hydration using an ethanol dilution series (100%, 90%, 70%, 50%
and 30%, each 5 minutes) with final rinsing in water. Spheroid
sections were stained with Mayer’s haematoxylin (Merck) for
5 minutes followed by a water rinse and then with 1% eosin
(Merck) for 3 minutes followed by a second water rinse. Sections
were then dehydrated in isopropanol and mounted with
Entellen (Merck) for microscopy imaging.
Proliferating cells were identified using a 5-bromo-2-deoxy-
uridine (BrdU) incorporation assay, involving incubation in
10 mM BrdU for 6 hours, followed by formaldehyde fixation. ForThis journal is ª The Royal Society of Chemistry 2011BrdU and HIF-1a immunostaining, antigens were made acces-
sible by placing the slides in a citrate buffer (0.01 M, pH 6.0) and
heating in a microwave (2  7 minutes). Following cooling,
sections from spheroids incubated with BrdU were further
treated for 10 minutes with 2 N HCl. All slides were then rinsed
twice in 1 PBS and further prepared in a humidity chamber.
Non-specific binding was blocked with 3% BSA/PBS/0.1%
Tween 20 for 1 hour followed by the addition of the primary
antibodies which were directed against BrdU (rat anti-BrdU,
Serotec, 1 : 25 in 0.3% BSA/1 PBS/0.1% Tween 20) or HIF-1a
(mouse anti-HIF-1a, Novus Biologicals, 1 : 25 in 0.3% BSA/1
PBS/0.1% Tween 20) and incubation for 1 hour, followed by 1
PBS washing (3  5 minutes). Slides were then incubated with
Cy2-conjugated rat or mouse secondary antibodies (Dianova,
Hamburg, 1 : 100 in 0.3% BSA/1 PBS/0.1% Tween 20) for
1 hour and washed with 1 PBS (3 5 minutes). The nuclei were
stained for 5 minutes with 40,6-diamidino-2-phenylindole (DAPI,
Invitrogen) at room temperature. Slides were mounted with
Mowiol solution and a laser confocal scanning microscope
(Fluoview 1000, Olympus) was used for fluorescent imaging.
Irinotecan dose–response analysis. A dose–response experiment
using the anti-cancer drug irinotecan was undertaken to identify
the altered chemosensitivity states of tumour spheroids. Arrays
with pitches of 400 and 1500 mm were used to culture spheroids
with irinotecan exposure for 3 days at concentrations ranging
from 3.16 mM to 1000 mM during pre-hypoxic and hypoxic
phases of culture. Monolayer cultures were used as experimental
controls. Microtitre plate wells were each seeded with 6  102
cells, cultured for 4 days at 37 C in a 6% CO2 atmosphere and
then exposed to irinotecan at concentrations ranging from 1 mM
to 3.16 mM for a further 3 days. The acid phosphatase assay was
used to measure the inhibitory effects of irinotecan on cell
viability.41,42 Following exposure the spheroids were washed
twice with 1 PBS, and then harvested by pipetting for transfer
into a 96-well plate. The spheroids were immersed in a 200 mL
volume of a 1 : 1 mixture of 1 PBS and 0.1 M sodium acetate
buffer containing 0.1% Triton X-100 and 400 mg p-nitrophenyl
phosphate (Pierce Biotech Inc.) and incubated for 90 minutes at
37 C in a 6% CO2 atmosphere. Phosphatase activity was
quenched by the addition of 10 mL of 1 N NaOH to each well and
within 10 minutes the absorbance at 405 nm was measured using
a plate reader (Multiskan FC, Thermo Scientific). The experi-
ment was undertaken in triplicate with each replicate involving
the measurement of 8 spheroids.Results and discussion
Culture of uniformly sized spheroids on thin film PDMS arrays
Spheroids were formed using a cell adhesion array prepared by
thin film PDMS microcontact printing.13 PDMS surfaces resist
cell adhesion and are well suited for confining cell patterns during
prolonged culture.12,43 The patterned PDMS film was typically
40 nm thick, with perforations exposing the underlying tissue
culture substrate to act as centres of cellular attachment for
assembly and growth into spheroids. A hexagonal array was used
throughout this study to provide equidistant spacing between
spheroids and maintain near-uniform diffusion gradientsLab Chip, 2011, 11, 419–428 | 421
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View Article Onlinesurrounding the spheroids. An adhesion island diameter of
150 mm was chosen for the culture of sufficiently large spheroids,
while also being suitably small to enable the formation of
spherical tissues and prevent the local formation of multiple,
heterogeneously sized spheroids.
Traditional spheroid production methods involve compart-
mentalising cells within droplets or wells for the aggregation of
the entire cell population over a period of 3–4 days. The array
method partitions small sub-populations of proliferating cells
within each adhesion island for growth into a compact cellular
construct. Expansion from a small sub-population may more
accurately reflect lineage expansion during in vivo tumour
development.44 Assembly and growth of HT29 human colon
carcinoma spheroids on arrays with a pitch of 450 mm are
documented in Fig. 1 and available as a time lapse video in the
ESI†. Cells were seeded for 24 hours followed by media exchange
to remove non-adherent (non-viable) cells and reveal a well
defined cellular array, with each adhesion island supporting 40–
50 cells (Fig. 1(A)). Following a further 24 hours of culture cell
division produces a super-confluent monolayer (Fig. 1(B)). At
this stage growth is constrained by the PDMS perimeter and the
absence of further space for adhesion leads to the formation of
a 3-D tissue, producing a hemispherical morphology by day 4
(Fig. 1(C)) and a spherical morphology with a diameter of
235 mm (SD 12) by day 10 (Fig. 1(D)). Strong cell–cell and cell–Fig. 1 Human HT29 colon carcinoma spheroid growth on arrays with
a 450 mm pitch: collections of cells adhered to the exposed areas of the
glass substrate within the first day (A), monolayers were formed by day 2
(B), hemispheres were formed by day 4 (C) and plateau phase spheroids
with a diameter 235 mm (SD  12) were formed by day 10 (D). Spheroid
growth during arrayed culture (E). A Boltzmann function was used to fit
the sigmoidal curve.
422 | Lab Chip, 2011, 11, 419–428matrix interactions produce a collection of cells with a smooth
surface. Indeed, during array-based culture E-cadherin gene
expression is significantly up-regulated (p < 0.001) to promote
cell–cell tethering and the formation of a tightly packed 3-D
cellular body, whereas a5b1 integrin expression remains unal-
tered (see ESI, Fig. S2†). To demonstrate the wider applicability
of the array method, spheroids were also formed from BT474
breast carcinoma and NCI-H1792 lung carcinoma cell lines (see
ESI, Fig. S3†). Other spheroid-forming cell lines, including
members of the NCI-DTP 60-cell line screen,1,4 are also likely to
be suitable for array-based culture.
Sigmoidal growth on the arrays into uniformly sized spheroids
with diameters of 254 mm (SD  21) is documented in Fig. 1(E).
Shown in Fig. 2(A and B) the resulting tissues have a spherical
morphology. The spheroids were harvested by pipetting and
embedded in an agarose hydrogel for 3-axis imaging (see
Fig. 2(C)). Circularity measurements of images from each axis
were used to determine the truly spherical nature of the tissues
(e.g. x ¼ 91%; y ¼ 93% and z ¼ 94%). Such sphericity is a pre-
requisite for a tissue model with radial internal mass transfer.
The sphericity also enables the tissue density to be determined
using sedimentation rate measurements.Mass production of tumour spheroids
Arrays can be used as mother dishes for the highly parallel
production of uniform tumour spheroids. The surface pattern
partitions spheroid assembly and growth. This requires a single
pipetting step to automate mass production, whereas individual
pipetting operations are required for the formation of each
spheroid by the hanging drop or the agarose overlay methods.
The array method therefore eliminates pipetting errors and
preparation is orders of magnitude faster. In addition, the array
format anchors the spheroids in place for ease of media
exchange without spheroid loss. The PDMS surface strongly
resisted non-specific cell adhesion and the arrays had high
across chip, chip-to-chip and batch-to-batch pattern occupancy
levels (>95%). To demonstrate the mass production capabilities,
arrays with 1675 adhesion islands were each placed in a well of
a standard 6-well culture plate (providing a total of 10 050
adhesion islands) for spheroid culture (see Fig. 3). An average
occupancy of 97.3% (9779 spheroids in total) resulted and, with
a 99.0% harvesting efficiency, 9678 uniformly sized spheroids
were obtained. Such levels of production ease requirements for
incubator space and can match the demands of high throughput
experimentation.Array pitch can be used to alter growth kinetics
To determine the limits of spheroid growth an experiment using
arrays with different pitches (from 400 to 2000 mm) was under-
taken. The different growth curves are documented in Fig. 4(A).
A pitch of 400 mm produced spheroids with diameters of 200 mm
(SD 11) by day 16. Arrays with a 700 mm pitch produced HT29
spheroids with diameters of 276 mm (SD  25) by day 17,
equivalent to HepG2 spheroids cultured on arrays with a 600 mm
pitch.34 Although these are the largest previously reported array-
cultured spheroids, these are dwarfed by spheroids cultured on
arrays with a 2000 mm pitch. Here, rapid and sustained growthThis journal is ª The Royal Society of Chemistry 2011
Fig. 2 SEM imaging of a formaldehyde-fixed array of uniformly shaped
spheroids (A) and an individual adherent spheroid (B). Agarose
embedding was used for 3-axis imaging (C) and circularity measurements
(x ¼ 91%; y ¼ 93%; and z ¼ 94%).
Fig. 3 Mass production of tumour spheroids on an array with a pitch of
450 mm. Image compilation of a 0.55 cm2 region of an array containing
137 uniformly sized spheroids following culture for 5 days.
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View Article Onlineenables the production of spheroids with diameters of 548 mm
(SD  45) by day 27. The sigmoidal growth characteristic indi-
cates that, irrespective of the pitch, nutrient availability and
waste removal ultimately become limiting during sustained
culture.
To distinguish array pitch (area) from spheroid number
(volume) factors, arrays with the same number (104) of adhesion
islands and different pitches (from 400 to 2000 mm, Fig. 4(B))
were used, along with arrays with the same pitch (400 mm) and
different numbers of spheroids (from 104 to 2411, Fig. 4(C)). The
number of adhesion islands per array had minimal impact on the
growth, whereas the pitch of the arrayed adhesion islands
dramatically affected growth (cell division rate), growth duration
and consequently the final spheroid size. As the array density is
reduced, from pitches of 400 mm up to 1250 mm, the diffusive
exchange of nutrients and waste becomes less limiting, leading to
enhanced growth. Gains in growth are not observed beyond
a pitch of $1250 mm (1.35 mm2 per spheroid), the extent of theThis journal is ª The Royal Society of Chemistry 2011diffusive-competition for media. With these array dimensions the
volume of available media instead becomes limiting. For
example, the 2000 mm pitch arrays provide 60 mL of media per
spheroid, a fraction of the 200 mL used in the liquid overlay
method. Under these conditions, the microarray format
produces smaller plateau phase spheroids than the liquid overlay
method which may in turn produce smaller spheroids than when
using spinner flasks. Growth kinetics are therefore dictated by
the chosen culture method and operating conditions. Growth on
the microarray could be enhanced by the use of larger media
volumes, more frequent media exchange (e.g. daily) or media
perfusion. Without these considerations, the large pitch
($1250 mm) arrays still produce spheroids with sufficiently large
(500 mm) dimensions to impart in vivo-like mass transfer
gradients and reflect the pathophysiological state of avascu-
larised tumour regions.
Growth kinetics were also evaluated by curve fitting using the
Gompertz equation, an established method for describing volu-
metric tumour spheroid growth.38 The reproducible morphology
of spheroids cultured on the array (see Fig. 2) enabled the
spheroid volume to be calculated using a capped spherical model.
In the ESI Fig. S4†, volumetric growth is plotted with Gompertz
curve fitting for spheroids cultured on arrays with pitches
ranging from 400 mm to 2000 mm. Curve fitting correlated well
with the data (r2 $ 97%). The correlation increased with pitch to
r2 $ 99% for the rapidly growing spheroids cultured on arrays
with pitches $1500 mm, indicating that these arrays can be used
to impart the same growth kinetics as other traditional spheroid
culture methods.
Spheroids were cultured on arrays with different pitches and
harvested at the plateau phase of growth for characterisation in
terms of diameter, cell number, density and sphericity (see
Table 1). The cell number was proportional to the spheroid
diameter (and volume). The spheroids were characteristically
dense, typically 1040 kg m3, a density equivalent to those of
in vivo tissues. This dense, robust character enables the spheroid
to be harvested without damage for off-chip investigations.
Circularity values from all 3 axes and all sizes were 90%,
indicating the formation of highly spherical tissue assemblies.
Both the highly spherical morphology and the densely organized
cellular structure are mandatory for an effective spheroid model.
The reproducibility of these different characteristics underscores
the value of array-based spheroid culture for the controlled
formation of tumour spheroids with sizes ranging from 200–
550 mm.Necrosis, proliferation and hypoxia marker profiles of plateau
phase spheroids
The spheroids were characterised in terms of proliferation,
expression of hypoxia markers and necrosis. Hematoxylin and
eosin stained median sections from plateau phase spheroids are
shown in Fig. 5 and clearly reveal central secondary necroses for
all three spheroid sizes (220 mm (A), 390 mm (B) and 550 mm (C)).
The largest spheroids were further characterised. A BrdU
incorporation assay was used to identify a narrow (25 mm)
proliferating layer of cells at the spheroid periphery (Fig. 5(D)),
and immunostaining identified widespread expression of hypoxia
inducible factor 1a (HIF-1a) with high levels surrounding theLab Chip, 2011, 11, 419–428 | 423
Fig. 4 Growth kinetics of spheroids cultured on arrays with pitches
ranging from 400 to 2000 mm (A). A Boltzmann function was used to fit
the sigmoidal curves. Spheroid diameters were highly uniform (SD #
10%). The available area per spheroid (array pitch: 400, 700, 1000, 1250
and 2000 mm) impacts final spheroid diameter (B). Each array contained
104 adhesion islands. With an array pitch of 400 mm, the media volume
available per spheroid (spheroid number: 104, 351, 739, 1306 and 2411)
had minimal effect on the final spheroid diameter (C). Data points are
mean values from triplicate conditions, each involving 15–30 diameter
measurements.
Fig. 5 Hematoxylin and eosin staining of median sections from
a 220 mm diameter spheroid (400 mm pitch; harvested day 16) (A),
a 390 mm diameter spheroid (1250 mm pitch; harvested day 17) (B) and a
550 mm diameter spheroid (2000 mm pitch; harvested day 27) (C). BrdU
incorporation (green) (D) and HIF-1a (green) (E) distribution mapping
by immunostaining of median sections from the largest spheroids. Nuclei
were stained with DAPI (blue).
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View Article Onlinenecrotic core (Fig. 5(E)). Combined, the different sections indi-
cate that sustained culture on the arrays also produces diffusion
gradients within the spheroid. The large spheroids formed on the
array can therefore be used as models which reflect theTable 1 Physical characteristics of tumour spheroids produced on array
measurements, with the cell number obtained by triplicate pooling of 30 sph
ments. The sphericity of the tumour spheroids was estimated by 3-axis imagin
lowest circularity value was nominated as the x-axis value and the highest as th
deviation values are prefixed with 
Array pitch/mm Harvested/day Diameter/mm Cell num
400 16 200  11 2009  1
700 17 276  25 5984  2
1000 17 324  30 9438  9
1250 17 379  38 15 676 
1500 27 531  54 —
2000 27 548  45 35 000
424 | Lab Chip, 2011, 11, 419–428pathophysiological state of naturally occurring avascularised
microtumours or tumour microregions. The array approach also
provides size tuning for the precise control of diffusion and thus
metabolic gradients (i.e. the gradient is inversely proportional to
the spheroid size). This degree of spatial control could be of
particular value for investigations into the effects of a range of
precisely defined biological gradients.
The expression of markers for proliferation, cell cycle arrest
and hypoxia by plateau phase HT29 spheroids was further
investigated by measuring gene expression levels of proliferating
cell nuclear antigen (PCNA), cyclin D, p21 and vascularising
endothelial growth factor (VEGF). Small (Ø z 200 mm) and
large (Ø z 500 mm) spheroids were compared with monolayers
cultured under hypoxic (1% oxygen) conditions as a control for
a depleted oxygen state. All samples were referenced to mono-
layer cells cultured under normoxia conditions (20% oxygen).
Documented in Fig. 6, both small and large spheroids haves with different pitches. Spheroid mean diameter values are from 30
eroids. Density values are the mean from 5 sedimentation rate measure-
g of 5 spheroids followed by circularity measurements using ImageJ. The
e z-axis value. Three values of 100% indicate perfect sphericity. Standard
ber Density/kg m3
Circularity (%)
x-axis y-axis z-axis
53 1044  7 87  5 91  3 94  2
97 1047  6 89  3 91  3 94  3
55 1048  5 90  2 91  2 94  2
709 1037  5 89  3 92  2 94  3
1033  5 89  2 91  2 92  2
1035  3 89  2 90  1 92  3
This journal is ª The Royal Society of Chemistry 2011
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View Article Onlineexpression patterns similar to those from monolayers cultured
under hypoxic conditions. Down regulation of PCNA and cyclin
D along with a marked increase in p21 levels indicate cell cycle
arrest. VEGF gene expression, a classic marker for hypoxic stress
(and relevant to a variety of tumour cells), was equally up-
regulated in the small (4.23-fold, SD 1.40) and large (4.28-fold,
SD  0.33) spheroids, and naturally strongly up-regulated in the
hypoxic monolayers (17.14-fold, SD  2.67). These data indicate
that both small and large spheroids experience hypoxia. In
addition to oxygen starvation other metabolic gradients and
pathophysiological states will also result during sustained
culture.Onset of necrosis and hypoxia
An experiment involving hematoxylin and eosin staining of
median spheroid sections was used to determine the onset of
secondary necrosis in spheroids cultured on 400 mm pitch and
1500 mm pitch arrays. As shown in ESI Fig. S5(A)†, on arrays
with a 400 mm pitch secondary necrosis became evident (<5% by
volume) by day 14 with spheroid diameters of 202 mm (SD 13).
On the 1500 mm pitch arrays, secondary necrosis also became
evident (<5% by volume) by day 14 in spheroids with diameters
of 389 mm (SD  26). This conflicts with observations that
necrosis onset is determined by scale, occurring within 100 to
200 mm diameter spheroids.34,45 However, these investigations
used microporous or microarray systems with pitches far beneath
the 1250 mm distance required for optimal array-based growth
(see Fig. 4(B)). These results point to the importance of both
scale and the culture history in the development of metabolic
gradients and secondary necrosis, and highlight the critical
importance of low microwell and microarray densities for the
sustained culture of large and viable spheroids.Fig. 6 PCNA (A), cyclin D (B), p21 (C) and VEGF (D) gene expression
levels from small (S: 200 mm diameter, day 14) and large (L: 500 mm
diameter, day 21) plateau phase spheroids were compared with levels
from hypoxic (H) monolayer cultures with 1% O2 levels. Values are
normalised relative to normoxia (N, 20% oxygen) monolayer cultures.
Data points are mean expression values  standard deviation from
triplicate conditions, with triplicate measurements from each sample.
This journal is ª The Royal Society of Chemistry 2011Secondary necrosis is a late stage response to nutrient depri-
vation, with oxygen availability being one of many factors
affecting cell metabolism and viability. To gain insight into the
earlier onset of hypoxic stress within the spheroids VEGF gene
expression was used as a diagnostic marker. Results are plotted
with diameter values in Fig. 7. Expression levels from spheroids
cultured on the dense 400 mm pitch arrays were significantly
(p < 0.001) up-regulated by day 7 with diameters of 179 mm
(SD  14). On the 1500 mm pitch arrays, VEGF expression
became significantly (p < 0.001) up-regulated by day 10 with
diameters of 320 mm (SD  29). The later response shows the
enhanced oxygen supply for rapid growth provided by the
1500 mm pitch arrays. Importantly, these results demonstrate
that modulation of the array density can be used to produce well
defined spatio-temporal models of developing pathophysiology.
Furthermore, the identification of pre-hypoxic and hypoxic (but
pre-necrotic) culture phases can be used to define windows of
operation for experiments aiming to elucidate the effect of
metabolic status on the responsiveness of spheroids to anti-
cancer treatments.
For applications requiring fully viable spheroids the micro-
array format can serve as a mother dish, like the hanging drop
method, with spheroid harvesting prior to the onset of metabolic
stress and pathophysiology. The robust, densely aggregated
character of the spheroids enables the harvesting of intact
spheroids by pipetting. However, spheroids harvested from
arrays with a 400 mm pitch at an early stage (day 7) of maturation
have a capped spherical morphology, requiring a further
24 hours culture within a non-adherent culture flask for natural
shape remodelling46 into a highly spherical tissue (x ¼ 91%;
y ¼ 95%; and z ¼ 96%).Spheroids have significantly reduced chemosensitivity
Chemotherapy investigations can be undertaken directly on the
array. We have demonstrated this using an in situ dose–response
experiment with the anti-cancer agent irinotecan. Arrays with
pitches of 400 mm and 1500 mm were selected to compare the
responses of rapid and slow growing spheroids. In addition, pre-
hypoxic and hypoxic (but pre-necrotic) phases of culture were
compared. The experiments entailed irinotecan exposure for
3 days followed by measuring the acid phosphatase activity,
a reliable indicator of the viable cell count of HT29 spheroids
with diameters as large as 650 mm.42
An irinotecan dose–response experiment involving monolayer
cultures gave a 50% inhibition concentration (IC50) value of
32 mM (95% CI 22–49), significantly (p < 0.001) lower than the
spheroid culture IC50 values. Documented in Fig. 8(A), pre-
hypoxic phase spheroids cultured on the 400 mm pitch arrays had
an IC50 of 102 mM (95% CI 49–239) which was significantly (p <
0.001) increased to 307 mM (95% CI 144–634) during the hypoxic
culture phase (see Fig. 8(A)). The pre-hypoxic phase spheroids
cultured on the 1500 mm pitch arrays had an IC50 of 62 mM (95%
CI 23–96) which was also significantly (p < 0.001) increased to
224 mM (95% CI 123–408) in the hypoxic culture phase (see
Fig. 8(B)). The culture conditions, treatment periods, spheroid
diameters, volumetric growth and IC50 values are summarised
in the ESI, Table S1†. Together the results demonstrate thatLab Chip, 2011, 11, 419–428 | 425
Fig. 7 Diameter (circles) and VEGF gene expression (bars) during
spheroid culture for up to 20 days on arrays with pitches of 400 mm (A)
and 1500 mm (B). Mean diameter values standard deviation are from 30
measurements. Expression levels are normalised relative to levels from
monolayer cultures. Data points are mean expression values  standard
deviation from triplicate conditions, with triplicate measurements from
each sample (*p < 0.001).
Fig. 8 Irinotecan dose–response results for spheroids cultured on
400 mm pitch (A) and 1500 mm pitch (B) arrays. The irinotecan concen-
tration is plotted against acid phosphatase activity (relative to untreated
controls) for monolayer cultures (triangles), pre-hypoxic spheroids (filled
circles) and hypoxic spheroids (white circles) following 3 days of exposure
to irinotecan. Curves were fitted using a Hill function with variable slope.
Mean values  standard deviation are from triplicate experiments, with
each replicate involving the measurement of 8 individual spheroids.
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View Article Onlinearray-cultured spheroids have markedly reduced sensitivity
towards irinotecan therapy than simple monolayer cultures.
The 3-D character, scale, cell proliferation rate and hypoxia
state are all factors which can lead to reduced drug efficacy. The
anti-tumour activity of irinotecan involves killing cells in S-phase
by inhibiting DNA synthesis.47,48 This mechanism explains the
reduced efficacy during treatment of the slowly proliferating
spheroids cultured on the 400 mm pitch arrays. As revealed by the
diameter and volumetric growth data (see ESI, Table S1†), the
rate of cell proliferation tends to zero (i.e. total cell cycle arrest)
in the hypoxic phase of culture, producing spheroids that are
only marginally larger (by 17 mm) than those cultured in the pre-
hypoxic culture phase. This loss of proliferation (without an
appreciable increase in size) acts to further curb the efficacy of
irinotecan (IC50 ¼ 307 mM). In comparison, the spheroids
cultured on the 1500 mm pitch arrays have high proliferation
rates throughout the experimental time scales (see ESI, Table
S1†), producing 240 mm diameter spheroids in the measured pre-
hypoxic growth phase and 363 mm diameter spheroids in the
measured hypoxic growth phase. Here the reduced chemo-
sensitivity may to be attributed to the limited penetration of
irinotecan into these large tissues. However, in the hypoxic phase
of culture it is uncertain whether the increased scale (by 123 mm)426 | Lab Chip, 2011, 11, 419–428and/or the altered metabolic state causally relate to the reduced
drug efficacy (IC50 ¼ 224 mM). Further experiments using the
microarray format are required to accurately discern the relative
contributions of the different factors.Future perspectives
The presented research has focussed on growth, scale and
hypoxia factors that affect sensitivity to treatment. A more
comprehensive understanding can be obtained by the quantita-
tive and spatial characterisation of other developing metabolic
transitions. In addition to chemosensitivity experiments, the
spheroid microarray format can be used for the evaluation of
radio- and immunotherapies, for the formation of more complex
spheroid co-cultures and for addressing fundamental lines of
research in cancer biology.2
The array format also has the potential to be used for growth
inhibition experiments with assay coordinates provided for in situ
monitoring. To clearly discern inhibitory effects, large pitch
arrays will be required to support optimal growth. This method
can be combined with automated imaging for a high contentThis journal is ª The Royal Society of Chemistry 2011
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View Article Onlinescreening approach to therapy testing. The in situ anti-cancer
therapy screening methods can be further improved by pack-
aging the spheroid arrays within the industry standard microtitre
plate format for lower volume drug testing. The PDMS material
used for cell patterning is also ideally suited for plasma bonding49
approaches to packaging. Each well of a 96-well plate (Ø ¼
6.5 mm) can accommodate 14 spheroids arrayed with a pitch of
1500 mm to provide more replicates for enhanced statistical
confidence, or 3 spheroids within each well of a 384-well plate
(Ø ¼ 3.0 mm) for higher throughput screening. Dense arrays,
with a 400 mm pitch, can be used to produce large numbers of
small spheroids; 480 within each well of a 96-well plate or 100
within each well of a 384-well plate. Such simple, yet powerful,
developments have the potential to greatly enhance the value of
the cell array format for spheroid research in both academic and
industrial settings.Conclusions
Microarrays can be used for the inherently automated and
scalable production of uniform tumour spheroids with diameters
as large as 550 mm. The array density dictates the growth
dynamics, with optimal growth kinetics on arrays with a pitch
of $1250 mm. The array format produces mass transfer gradients
surrounding and within the spheroids. Coupled with precision
size control array-based culture can be used to produce spatio-
temporal tissue models for understanding the development of
metabolic gradients and pathophysiological states. Fully viable
spheroids can be readily harvested or remain in situ and used to
investigate the impact of scale, cell proliferation rate and meta-
bolic status on the responsiveness to candidate anti-cancer
therapies. Together these developments portray the large
potential of the array format to support the widespread adoption
of the tumour spheroid model, provide detailed insights into
responses to pathophysiological gradients and aid the high
information content screening of new anti-cancer treatment
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